InflaRx

InflaRx develops inhibitors for the C5a complement factor. Lead candidate vilobelimab is an anti-C5a antibody for autoimmune and inflammatory diseases.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2017
Stage of Initial Investment
Series D
Initial Investment Year
2017
Infla Rx Hover Image